Blood Pressure and Outcomes in Very Old Hypertensive Coronary Artery Disease Patients: An INVEST Substudy

被引:126
作者
Denardo, Scott J. [1 ]
Gong, Yan [2 ]
Nichols, Wilmer W. [1 ]
Messerli, Franz H. [3 ,4 ]
Bavry, Anthony A. [1 ]
Cooper-DeHoff, Rhonda M. [1 ,6 ]
Handberg, Eileen M. [1 ]
Champion, Annette [5 ]
Pepine, Carl J. [1 ]
机构
[1] Univ Florida, Coll Med, Div Cardiovasc Med, Gainesville, FL 32610 USA
[2] Univ Florida, Ctr Pharmacogenom, Coll Pharm, Gainesville, FL 32610 USA
[3] St Lukes Roosevelt Hosp, Div Cardiol, New York, NY USA
[4] Columbia Univ, Coll Med & Phys, New York, NY USA
[5] Abbott Lab, Abbott Pk, IL USA
[6] Univ Florida, Dept Pharmacotherapy & Translat Res, Coll Pharm, Gainesville, FL 32610 USA
关键词
Age; Blood pressure control; Coronary artery disease; Elderly; Epidemiology; Hypertension; MAJOR CARDIOVASCULAR EVENTS; VERAPAMIL SR-TRANDOLAPRIL; METAANALYSIS; AGE; RESTENOSIS; PREVENTION; REGIMENS; THERAPY; PEOPLE; RISK;
D O I
10.1016/j.amjmed.2010.02.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Our understanding of the growing population of very old patients (aged >= 80 years) with coronary artery disease and hypertension is limited, particularly the relationship between blood pressure and adverse outcomes. METHODS: This was a secondary analysis of the INternational VErapamil SR-Trandolapril STudy (INVEST), which involved 22,576 clinically stable hypertensive coronary artery disease patients aged >= 50 years. The patients were grouped by age in 10-year increments (aged >= 80, n = 2180; 70-<80, n = 6126; 60-<70, n = 7602; <60, n = 6668). Patients were randomized to either verapamil SR- or atenolol-based treatment strategies, and primary outcome was first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: At baseline, increasing age was associated with higher systolic blood pressure, lower diastolic blood pressure, and wider pulse pressure (P < .001). Treatment decreased systolic, diastolic, and pulse pressure for each age group. However, the very old retained the widest pulse pressure and the highest proportion (23.6%) with primary outcome. The adjusted hazard ratio for primary outcomes showed a J-shaped relationship among each age group with on-treatment systolic and diastolic pressures. The systolic pressure at the hazard ratio nadir increased with increasing age, highest for the very old (140 mm Hg). However, diastolic pressure at the hazard ratio nadir was only somewhat lower for the very old (70 mm Hg). Results were independent of treatment strategy. CONCLUSION: Optimal management of hypertension in very old coronary artery disease patients may involve targeting specific systolic and diastolic blood pressures that are higher and somewhat lower, respectively, compared with other age groups. Published by Elsevier Inc. The American Journal of Medicine (2010) 123, 719-726
引用
收藏
页码:719 / 726
页数:8
相关论文
共 22 条
[1]   Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis [J].
Bangalore, Sripal ;
Messerli, Franz H. ;
Franklin, Stanley S. ;
Mancia, Giuseppe ;
Champion, Annette ;
Pepine, Carl J. .
EUROPEAN HEART JOURNAL, 2009, 30 (11) :1395-1401
[2]   Treatment of hypertension in patients 80 years of age or older [J].
Beckett, Nigel S. ;
Peters, Ruth ;
Fletcher, Astrid E. ;
Staessen, Jan A. ;
Liu, Lisheng ;
Dumitrascu, Dan ;
Stoyanovsky, Vassil ;
Antikainen, Riitta L. ;
Nikitin, Yuri ;
Anderson, Craig ;
Belhani, Alli ;
Forette, Francoise ;
Rajkumar, Chakravarthi ;
Thijs, Lutgarde ;
Banya, Winston ;
Bulpitt, Christopher J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (18) :1887-1898
[3]   Evaluation of the effect of oral verapamil on clinical outcome and angiographic -: Restenosis after percutaneous coronary intervention -: The randomized, double-blind, placebo-controlled, multicenter verapamil slow-release for prevention of cardiovascular events after angioplasty (VESPA) trial [J].
Bestehorn, HP ;
Neumann, FJ ;
Büttner, HJ ;
Betz, P ;
Stürzenhofecker, P ;
von Hodenberg, E ;
Verdun, A ;
Levai, L ;
Monassier, JP ;
Roskamm, H .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :2160-2165
[4]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[5]   Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials [J].
Gueyffier, F ;
Bulpitt, C ;
Boissel, JP ;
Schron, E ;
Ekbom, T ;
Fagard, R ;
Casiglia, E ;
Kerlikowske, A ;
Coope, J .
LANCET, 1999, 353 (9155) :793-796
[6]  
Inzitari Marco, 2005, Aging Clin Exp Res, V17, P6
[7]   β-blockers reduce the incidence of clinical restenosis:: Prospective study of 4840 patients undergoing percutaneous coronary revascularization [J].
Jackson, JD ;
Muhlestein, JB ;
Bunch, TJ ;
Bair, TL ;
Horne, BD ;
Madsen, TE ;
Lappé, JM ;
Anderson, JL .
AMERICAN HEART JOURNAL, 2003, 145 (05) :875-881
[8]  
Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8
[9]  
Lewington S, 2003, LANCET, V361, P1060
[10]   Are β-blockers efficacious as first-line therapy for hypertension in the elderly?: A systematic review [J].
Messerli, FH ;
Grossman, E ;
Goldbourt, U .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (23) :1903-1907